TrialRheumatology (Oxford, England)2019

Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.

Naoki Ishiguro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.